License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)	3 Months Ended
	Mar. 31, 2022 USD ($) performance_obligation	Mar. 31, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	$ 61,699,000	$ 52,304,000
Deferred revenue	75,796,000
Revenue recognized	6,602,000	5,382,000
Deferred revenue, net of current portion	65,356,000			$ 21,474,000
Short-term deferred revenue	10,440,000			20,906,000
Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable	24,316,000	3,539,000		$ 19,094,000	$ 3,045,000
Mitsubishi Tanabe Pharma Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	1,600,000
Mitsubishi Tanabe Pharma Corporation | License Collaboration And Other Revenue, Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	300,000	0
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	$ 25,000,000
Mitsubishi Tanabe Pharma Corporation | MTPC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations | performance_obligation	2
Deferred revenue	$ 0
Deferred revenue, net of current portion	0
Short-term deferred revenue	0
Mitsubishi Tanabe Pharma Corporation | MTPC Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	15,000,000
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received	20,000,000
Cost of research services	20,500,000
Milestone revenue	10,000,000
Deferred revenue	0
Accounts receivable	0
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue	10,000,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received			$ 10,400,000
Accounts receivable	0
Revenue recognized	0	0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable	200,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Other Current Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Short-term deferred revenue	1,900,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Other Noncurrent Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue, net of current portion	0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized	7,600,000	$ 0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	12,900,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Other Current Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	18,300,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Other Noncurrent Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	5,000,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Contract With Customer, Liability
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	$ 0